Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Form 8.5 (EPT/RI) - PPHE Hotel Group Limited
-
Form 8.5 (EPT/RI) - Alternative Income REIT Plc
-
Form 8.5 (EPT/RI) - Kore Potash Plc
-
DouYu International Holdings Limited Reports First Quarter 2026 Unaudited Financial Results
-
Li Auto Inc. Announces Unaudited First Quarter 2026 Financial Results
-
Form 8.3 - [ADVANCED MEDICAL SOLUTIONS GROUP PLC - 27 05 2026] - (CGWL)
-
Presentation materials for AB Civinity bond issue
-
Futu Announces First Quarter 2026 Unaudited Financial Results
-
Anaveon Reports Clinical Benefit of ANV600 in the EXPAND-1 Phase 1 Clinical Trial at ASCO 2026 and Actively Seeks Partners for its Legacy Oncology Portfolio
-
Willis: Leaders must move from caution to control as AI reshapes risk and resilience
-
XL‑protein Launches Spin-Off PASylANTA Therapeutics to Develop Long‑Acting IL‑1Ra Biobetters
-
SBTi validation of FLSmidth’s updated science-based targets
-
Stellar Alpina Raises CHF 3.5M to Build Detonation-Based Propulsion for Mobility After Launch
-
Share Buyback Transaction Details May 21 – May 27, 2026
-
Havila Kystruten AS: Notice of Annual General Meeting June 11th, 2026.
-
ViCentra Scales Commercial Manufacturing, Triples Capacity and Strengthens Unit Economics
-
Synklino announces first patient dosed in Phase 1 trial of SYN002 for CMV prevention in kidney transplantation
-
Fixico and Caliber join forces to reshape fleet repair in the United States
-
LIFT Files NI 43-101 Technical Report on the Adina-Galinée Lithium Project, Quebec, Canada
-
Theolytics’ Ongoing US Phase 1 OCTOPOD-IP Trial of THEO-260 in Ovarian Cancer to be Presented as a Trial in Progress at ASCO 2026
-
Groundbreaking therapy for advanced heart failure: Outcomes of the BIOVAT-HF clinical trial published in NEJM
-
Theolytics’ Ongoing US Phase 1 OCTOPOD-IP Trial of THEO-260 in Ovarian Cancer to be Presented as a Trial in Progress at ASCO 2026
-
SCOR successfully sponsors a new catastrophe bond, Atlas Capital DAC Series 2026-1
-
Analyst report highlights Q1 2026 bookings of c.€2.5 million, implying an annualised run-rate above €10 million
-
ARKAY Beverages Expands Its Zero-Proof Portfolio With BEYOND SPIRITS and BEYOND WHISKY Plant-Based
-
Vilmorin & Cie receives a new round of long-term research financing from the European Investment Bank
-
Pulsar Helium Welcomes Landmark Minnesota Helium Regulation as Topaz Advances Toward First Production Amid Global Helium Shortage
-
NBPE Announces Transaction in Own Shares
-
Trogenix doses first patient in Phase I/II clinical trial of TGX-007 gene therapy for glioblastoma
-
Holding(s) in Company
-
Enterome receives U.S. FDA Orphan Drug Designation for EO2463 OncoMimics™ to treat “watch-and-wait” indolent non-Hodgkin lymphoma
-
2026 World Intelligence Expo kicks off in north China's Tianjin
-
New late-breaking data reinforces IQIRVO®’s impact on ALP, fatigue and pruritus in PBC
-
VERAXA Biotech Strengthens Financial Position with $27.5 Million Principal Amount Senior Secured Note Financing and $50 Million Share Purchase Agreement
-
Basilea receives further USD 13 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam
-
Azerion publishes Interim Unaudited Financial Results Q1 2026
-
Origins Network Appoints Robles Carlos as CEO, Doubling Down on Blockchain Infrastructure and AI-Driven User Growth
-
2026 World Intelligence Expo kicks off in north China's Tianjin
-
argenx to Host Myositis R&D Webinar on June 23, 2026
-
Banqup Group announces change at the helm of its management
-
Start of Day Message
-
argenx to Host Myositis R&D Webinar on June 23, 2026
-
Result of the Initial Public Offering of the shares of BioMar Group A/S on Nasdaq Copenhagen
-
Press Release: Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease
-
Aegon announces agreement with Vereniging Aegon and publishes proposal for US-aligned governance framework
-
Lerøy Seafood Group ASA: Ex dividend
-
Sportradar Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Sportradar Group AG - SRAD
-
Wolf Valley Homes Launches Forge Reserve Collection of Luxury Tiny Homes and Park Model Cabins During Spring and Memorial Day Sales Event
-
Crypto News: Pepeto Presale Stage Sells Out Ahead of Schedule While the XRP Price Prediction Asks if $10 Is Reachable After Record ETF Month
-
Futu Announces Cumulative Repurchases of Approximately US$418 Million Worth of ADSs Under Share Repurchase Program

